At Britannia Pharmaceuticals Ltd. our primary field of interest is the development of speciality neurology medicines. Though we do not do in-house discovery, we are constantly searching out new technologies where we can apply our experience in the field to invest in and facilitate next-generation therapies.
In addition to this, as an organisation we are keen to partner with healthcare professionals and organisations in data generation to increase the understanding of how our current treatments can make a positive difference to the lives of people living with Parkinson’s disease.
Our Current Areas of Research Interest based on our strategic priorities are:
Disease State: Parkinson’s Disease
• Identifying the most appropriate time to initiate Device-Aided Therapies (DAT)
• Sequencing of DATs with a focus on patient selection (choosing the right therapy for the right patient)
• Identification of patient sub-types for specific DATs
• Identifying how the use of AI can enhance the experience of patients with APD (Advanced Parkinson’s Disease)
Compound: Levodopa, Entacapone, Carbidopa, Intestinal Gel (LECIG)
• The impact of LECIG treatment on Non-Motor Symptoms
• The clinical impact of continuous COMT inhibition
• Understanding the use of LECIG in combination with, or after failure, with other DATs
• Characterising APD medication management to achieve monotherapy with LECIG
• Further understanding the characteristics of patients likely to derive benefit from LECIG
• LECIG efficacy and safety profile in subpopulations of APD patients
• Evaluation of the efficacy of LECIG using technology such as innovative imaging techniques or wearable technologies
• The impact of continuous 24-hour LECIG therapy on motor and non-motor symptoms of PD, short, medium and long-term effects.
• In patients previously treated with subcutaneous foslevodopa/foscarbidopa or levodopa/carbidopa intestinal gel (LCIG), characterising the impact of LECIG on:
– Motor symptoms e.g. morning akinesias and dystonia, fluctuations (reduction of “off” and quality of “on”), dyskinesias, freezing, motion.
– Non-motor symptoms
– Patient and caregiver satisfaction and experiences
– Quality of Life
– Healthcare resource use
• Polyneuropathy research: Levels of HCY and vitamins B12, B6, and B1 in people treated with LECIG.
Compound: Apomorphine
• Evaluating apomorphine efficacy and tolerability in sub-populations of APD patients
• Understanding the use of apomorphine in combination with or after failure with other therapies
• Further understanding the characteristics of patients likely to derive benefit from apomorphine
• Exploring the influence of genetic factors on individual responses to apomorphine therapy, including genetic markers associated with treatment efficacy and adverse effects
• Cost-effectiveness of apomorphine treatment vs. other DATs
• Comparisons of efficacy and safety profile of Parkinson’s disease subcutaneous therapies
• Benefits of using apomorphine in other indications
